Assessment of methodological quality
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Total |
| Winkler et al 199916 | U | U | U | N | N | U | Y | Y | Y | Y | Y | Y | Y | 18/26 |
| Gonzalez-Ortiz et al 201015 | U | U | Y | Y | Y | U | Y | Y | Y | Y | Y | Y | Y | 23/26 |
| Stracke et al 200831 | Y | U | Y | U | Y | U | Y | Y | Y | Y | Y | Y | Y | 23/26 |
| Rabbani et al 200919 | Y | Y | Y | Y | Y | Y | Y | U | U | Y | Y | Y | Y | 24/26 |
| Shahmiri et al 201343 | U | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 25/26 |
| Alkhalaf et al 201029 | U | U | Y | Y | Y | U | Y | Y | Y | Y | Y | Y | Y | 23/26 |
JBI critical appraisal checklist for randomised controlled trials: Q1: Was true randomisation used for assignment of participants to treatment groups? Q2: Was allocation to treatment groups concealed? Q3: Were treatment groups similar at the baseline? Q4: Were participants blind to treatment assignment? Q5: Were those delivering treatment blind to treatment assignment? Q6: Were outcomes assessors blind to treatment assignment? Q7: Were treatments groups treated identically other than the intervention of interest? Q8: Was follow-up complete, and if not, were strategies to address incomplete follow-up utilised? Q9: Were participants analysed in the groups to which they were randomised? Q10: Were outcomes measured in the same way for treatment groups? Q11: Were outcomes measured in a reliable way? Q12: Was appropriate statistical analysis used? Q13: Was the trial design appropriate, and any deviations from the standard RCT design (individual randomisation, parallel groups) accounted for in the conduct and analysis of the trial?
N=0, U=1, Y=2 points.
N, no; NA, not applicable; RCT, randomised controlled trials; U, unclear; Y, yes.